新型分支支架治疗胸腹主动脉瘤的多中心意大利注册研究初步结果
该多中心回顾性队列研究纳入16例胸腹主动脉瘤或复杂腹主动脉疾病患者,使用新型分支支架行腔内修复。技术成功率87.5%,主动脉相关死亡率为19%,脊髓缺血未发生,随访期无I/III型内漏,桥接支架一期通畅率98%。
要点
- 新型分支支架治疗复杂主动脉疾病技术成功率87.5%,主动脉相关死亡率19%。
- 随访期无I/III型内漏,桥接支架一期通畅率98%,无主动脉再干预。
- 脊髓缺血未发生,但样本量小、随访短,需谨慎解读。
核心结论
- 使用新型分支支架行腔内修复复杂主动脉瘤技术成功率高、并发症可接受。
- 19%死亡率虽高,但在高危队列中可耐受,早期随访移植物相关结果良好。
研究设计与样本
- 多中心、回顾性、观察性队列研究,连续纳入16例接受新型分支支架治疗的患者。
- 择期患者采用分期手术策略和脊髓引流,主要终点为技术成功、早期(≤30天)死亡、晚期(≥30天)生存和无不良主动脉事件。
主要发现
- 16例中Crawford I型1例、II型7例、III型1例、IV型5例,另2例复杂肾旁腹主动脉病变。
- 13例男性(81%)、3例女性(19%),中位年龄72.5岁(IQR 69-78岁)。
- 中位动脉瘤直径65 mm(IQR 58-81 mm),中位EuroSCORE预测死亡率18%(IQR 12%-36%)。
- 64条内脏血管中62条(96.9%)置入支架,技术成功14例(87.5%),主动脉相关累积死亡率19%。
- 平均随访8±4个月(范围2-15个月),无I/III型内漏,桥接支架一期通畅率98%,无主动脉再干预。
临床怎么用
- 对于高危复杂胸腹主动脉瘤患者,新型分支支架可作为腔内修复的一种选择。
- 择期手术采用分期策略和脊髓引流可能有助于降低脊髓缺血风险。
局限性
- 样本量小(16例),随访时间短(平均8个月),结论需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The study purpose was to present early outcomes of patients treated for thoracoabdominal aortic aneurysms or complex abdominal aortic diseases using endovascular repair with a new branched endograft. METHODS: This multicenter, retrospective, observational cohort study included all patients treated with a new branched endograft. All elective patients were treated with a staged operative strategy and spinal drainage Primary outcomes of interest were technical success, early (≤30 days) mortality, and late (≥30 days) survival, and freedom from adverse aortic events. RESULTS: A total of 16 consecutive patients were treated for Crawford's extent type I (n = 1), type II (n = 7), type III (n = 1), and type IV (n = 5) endoleaks, with an additional two complex pararenal abdominal aortic lesions (enlarging type Ia endoleak, n = 1; anastomotic pseudoaneurysm, n = 1). There were 13 male (81%) and 3 female (19%) patients with a median age of 72.5 years (interquartile range [IQR], 69-78 years). The median diameter of the aortic aneurysm was 65 mm (IQR, 58-81 mm) and the median EuroSCORE prediction for mortality was 18% (IQR, 12%-36%). Thoracoabdominal aortic aneurysm was secondary to a previous dissection in four patients. A total of 62 of the 64 visceral vessels (96.9%) were stented. Technical success was achieved in 14 (87.5 %) and the cumulative aorta-related mortality rate was 19%. Spinal cord ischemia did not occur. The mean follow-up was 8 ± 4 months (range, 2-15 months). No type I or type III endoleaks were detected. Primary bridging stent patency was 98% (one asymptomatic thrombotic occlusion of a celiac trunk branch). No aortic reintervention was required. CONCLUSIONS: Endovascular repair of complex aortic aneurysms with this new branched endograft can be performed with high technical success and acceptable morbidity. A 19% mortality is quite high; however, it is tolerable in such a high-risk cohort. The survival rate was acceptable, and graft-related outcomes at early follow-up included an absence of threatening endoleaks and a high target visceral vessel patency.
引用
- Angiletta D, Piffaretti G, Patruno I, et al. Preliminary results from a multicenter Italian registry on the use of a new branched device for the treatment of thoracoabdominal aortic aneurysms. J Vasc Surg. 2021. PMID: 33548421. doi:10.1016/j.jvs.2020.12.092
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。